Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sphingosine | 4 | 2018 | 22 | 0.960 |
Why?
|
| Lysophospholipids | 4 | 2018 | 48 | 0.930 |
Why?
|
| Postpartum Hemorrhage | 1 | 2024 | 9 | 0.900 |
Why?
|
| Sex Factors | 2 | 2021 | 451 | 0.750 |
Why?
|
| Nasal Mucosa | 1 | 2021 | 12 | 0.730 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 122 | 0.630 |
Why?
|
| Apolipoproteins M | 1 | 2018 | 1 | 0.630 |
Why?
|
| Inflammation | 2 | 2021 | 605 | 0.620 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 41 | 0.610 |
Why?
|
| Isoantibodies | 2 | 2014 | 15 | 0.580 |
Why?
|
| Platelet Transfusion | 2 | 2014 | 29 | 0.580 |
Why?
|
| Leukapheresis | 1 | 2014 | 3 | 0.480 |
Why?
|
| Blood Group Incompatibility | 1 | 2014 | 2 | 0.480 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 20 | 0.470 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 18 | 0.460 |
Why?
|
| Thrombin | 2 | 2024 | 68 | 0.440 |
Why?
|
| Fibrinolysin | 2 | 2024 | 15 | 0.280 |
Why?
|
| Pregnancy | 3 | 2024 | 1153 | 0.270 |
Why?
|
| Blood Platelets | 2 | 2018 | 203 | 0.230 |
Why?
|
| Female | 10 | 2024 | 14658 | 0.220 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 38 | 0.220 |
Why?
|
| Postpartum Period | 1 | 2024 | 67 | 0.220 |
Why?
|
| Male | 11 | 2021 | 13034 | 0.200 |
Why?
|
| Blood Coagulation | 1 | 2023 | 116 | 0.200 |
Why?
|
| Gene Frequency | 2 | 2013 | 182 | 0.200 |
Why?
|
| Atherosclerosis | 2 | 2014 | 95 | 0.200 |
Why?
|
| Mice | 3 | 2021 | 4472 | 0.190 |
Why?
|
| Thrombosis | 1 | 2023 | 147 | 0.190 |
Why?
|
| Humans | 15 | 2024 | 27175 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2021 | 265 | 0.170 |
Why?
|
| Ultracentrifugation | 1 | 2018 | 8 | 0.160 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 29 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2018 | 35 | 0.150 |
Why?
|
| Interleukin-33 | 1 | 2018 | 5 | 0.150 |
Why?
|
| Th2 Cells | 1 | 2018 | 14 | 0.150 |
Why?
|
| Animals | 4 | 2021 | 10082 | 0.150 |
Why?
|
| Chitin | 1 | 2018 | 10 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 41 | 0.150 |
Why?
|
| Erythrocytes | 1 | 2018 | 84 | 0.150 |
Why?
|
| Asthma | 1 | 2018 | 57 | 0.140 |
Why?
|
| Kinetics | 1 | 2018 | 538 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2018 | 246 | 0.140 |
Why?
|
| Dendritic Cells | 1 | 2018 | 143 | 0.140 |
Why?
|
| Protein Binding | 1 | 2018 | 636 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1496 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2018 | 977 | 0.130 |
Why?
|
| Mice, Knockout | 1 | 2018 | 793 | 0.130 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2015 | 15 | 0.120 |
Why?
|
| Sphingomyelins | 1 | 2015 | 11 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1573 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 54 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2013 | 134 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 154 | 0.100 |
Why?
|
| Isoantigens | 1 | 2012 | 4 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 123 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 66 | 0.100 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2012 | 3 | 0.100 |
Why?
|
| Serotonin | 1 | 2012 | 16 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 143 | 0.100 |
Why?
|
| Neutrophils | 1 | 2012 | 179 | 0.090 |
Why?
|
| Adult | 6 | 2015 | 7510 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 1943 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2464 | 0.070 |
Why?
|
| Adolescent | 1 | 2014 | 2996 | 0.070 |
Why?
|
| Middle Aged | 4 | 2014 | 6918 | 0.070 |
Why?
|
| Aged | 1 | 2014 | 5232 | 0.060 |
Why?
|
| Indicator Dilution Techniques | 1 | 2024 | 7 | 0.060 |
Why?
|
| Factor Xa | 1 | 2023 | 13 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 33 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2023 | 28 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 53 | 0.050 |
Why?
|
| Alleles | 2 | 2013 | 347 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2018 | 6 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 254 | 0.040 |
Why?
|
| Nasal Obstruction | 1 | 1996 | 6 | 0.030 |
Why?
|
| Sensation | 1 | 1996 | 12 | 0.030 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hybridomas | 1 | 2014 | 17 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2014 | 15 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 20 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 54 | 0.030 |
Why?
|
| Antigens, Human Platelet | 1 | 2013 | 5 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 13 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2014 | 48 | 0.030 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2013 | 38 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 206 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 244 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 317 | 0.030 |
Why?
|
| Anemia, Aplastic | 1 | 1992 | 3 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2012 | 6 | 0.030 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1992 | 6 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1992 | 5 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 1992 | 16 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 1992 | 11 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 1992 | 17 | 0.020 |
Why?
|
| Quinolones | 1 | 1992 | 23 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 112 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 143 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 128 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 736 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 681 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 324 | 0.020 |
Why?
|
| Vasodilation | 1 | 2012 | 114 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 1992 | 79 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 864 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 445 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 181 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 667 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 305 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 1374 | 0.020 |
Why?
|
| Adiposis Dolorosa | 1 | 1986 | 1 | 0.020 |
Why?
|
| Glycerides | 1 | 1986 | 2 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1986 | 103 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 1978 | 6 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1978 | 10 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1978 | 27 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1978 | 117 | 0.010 |
Why?
|
| Airway Resistance | 1 | 1996 | 5 | 0.010 |
Why?
|
| Plethysmography, Whole Body | 1 | 1996 | 3 | 0.010 |
Why?
|
| Ontario | 1 | 1996 | 11 | 0.010 |
Why?
|
| Japan | 1 | 1996 | 23 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 1996 | 21 | 0.010 |
Why?
|
| Manometry | 1 | 1996 | 38 | 0.010 |
Why?
|
| Perception | 1 | 1996 | 85 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1992 | 110 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1992 | 293 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 241 | 0.000 |
Why?
|
| Glucose | 1 | 1986 | 198 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1986 | 181 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1978 | 463 | 0.000 |
Why?
|